The Korean journal of internal medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지
DOI QR코드

DOI QR Code

Long-term study of the association of adipokines and glucose variability with diabetic complications

  • Cha, Jin Joo (Department of Nephrology, Korea University Ansan Hospital) ;
  • Min, Hye Sook (Department of Nephrology, Korea University Ansan Hospital) ;
  • Kim, Kitae (Department of Nephrology, Korea University Ansan Hospital) ;
  • Lee, Mi Jin (Department of Nephrology, Korea University Ansan Hospital) ;
  • Lee, Mi Hwa (Department of Nephrology, Korea University Ansan Hospital) ;
  • Kim, Jung Eun (Department of Nephrology, Korea University Ansan Hospital) ;
  • Song, Hye Kyoung (Department of Nephrology, Korea University Ansan Hospital) ;
  • Cha, Dae Ryong (Department of Nephrology, Korea University Ansan Hospital) ;
  • Kang, Young Sun (Department of Nephrology, Korea University Ansan Hospital)
  • Received : 2016.04.11
  • Accepted : 2016.06.06
  • Published : 2018.03.01
⟨ Previous Next ⟩

Abstract

Background/Aims: Recent studies have suggested an important role of adipokines in the development of insulin resistance and diabetes mellitus. The clinical relevance of adipokines on long-term outcomes in patients with diabetes and chronic kidney disease is uncertain. The purpose of this study was to identify a predictable factor in patients with long-term diabetic complications. Methods: A total of 161 diabetic individuals were followed-up from 2002 to 2013. Circulating plasma levels of adiponectin, glypican-4, irisin, visfatin, and visit-to-visit glucose variability were measured in diabetic patients. Associations among adipokines and variable metabolic parameters and microvascular, and macrovascular complications were evaluated. Results: Plasma adiponectin and glypican-4 levels were significantly increased in patients with renal insufficiency. These adipokines were negatively associated with estimated glomerular filtration rate and positively associated with urinary albumin excretion. The relative risk of renal progression to dialysis increased independently with increasing level of adiponectin. Glypican-4 and visfatin were not predictive of any microvascular or macrovascular complications. Glucose variability increased the risk of diabetic nephropathy and cerebrovascular complications. Conclusions: Adiponectin and glypican-4 were associated with renal function and might be able to predict renal progression. Glucose variability was a predictable factor for diabetic nephropathy and cerebrovascular complications.

Keywords

Acknowledgement

Supported by : Korea University

References

  1. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001;286:327-334. https://doi.org/10.1001/jama.286.3.327
  2. Devaraj S, Glaser N, Griffen S, Wang-Polagruto J, Miguelino E, Jialal I. Increased monocytic activity and biomarkers of inflammation in patients with type 1 diabetes. Diabetes 2006;55:774-779. https://doi.org/10.2337/diabetes.55.03.06.db05-1417
  3. Lafontan M. Adipose tissue and adipocyte dysregulation. Diabetes Metab 2014;40:16-28. https://doi.org/10.1016/j.diabet.2013.08.002
  4. Romacho T, Elsen M, Rohrborn D, Eckel J. Adipose tissue and its role in organ crosstalk. Acta Physiol (Oxf ) 2014; 210:733-753. https://doi.org/10.1111/apha.12246
  5. Mills KT, Hamm LL, Alper AB, et al. Circulating adipocytokines and chronic kidney disease. PLoS One 2013;8:e76902. https://doi.org/10.1371/journal.pone.0076902
  6. Adamczak M, Chudek J, Wiecek A. Adiponectin in patients with chronic kidney disease. Semin Dial 2009;22:391-395. https://doi.org/10.1111/j.1525-139X.2009.00587.x
  7. Briffa JF, McAinch AJ, Poronnik P, Hryciw DH. Adipokines as a link between obesity and chronic kidney disease. Am J Physiol Renal Physiol 2013;305:F1629-F1636. https://doi.org/10.1152/ajprenal.00263.2013
  8. Min HS, Kim JE, Lee MH, et al. Effects of Toll-like receptor antagonist 4,5-dihydro-3-phenyl-5-isoxasole acetic acid on the progression of kidney disease in mice on a high-fat diet. Kidney Res Clin Pract 2014;33:33-44. https://doi.org/10.1016/j.krcp.2013.11.002
  9. Deng Y, Scherer PE. Adipokines as novel biomarkers and regulators of the metabolic syndrome. Ann N Y Acad Sci 2010;1212:E1-E19.
  10. Cha JJ, Hyun YY, Jee YH, et al. Plasma leptin concentrations are greater in type II diabetic patients and stimulate monocyte chemotactic peptide-1 synthesis via the mitogen- activated protein kinase/extracellular signal-regulated kinase pathway. Kidney Res Clin Pract 2012;31:177-185. https://doi.org/10.1016/j.krcp.2012.06.004
  11. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998;15:539-553. https://doi.org/10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S
  12. Chamberlain JJ, Rhinehart AS, Shaefer CF Jr, Neuman A. Diagnosis and management of diabetes: synopsis of the 2016 American Diabetes Association standards of medical care in diabetes. Ann Intern Med 2016;164:542-552. https://doi.org/10.7326/M15-3016
  13. Tuttle KR, Bakris GL, Bilous RW, et al. Diabetic kidney disease: a report from an ADA Consensus Conference. Am J Kidney Dis 2014;64:510-533. https://doi.org/10.1053/j.ajkd.2014.08.001
  14. Guo X, Zhou G, Guo M, Cheung AK, Huang Y, Beddhu S. Adiponectin retards the progression of diabetic nephropathy in db/db mice by counteracting angiotensin II. Physiol Rep 2014;2:e00230. https://doi.org/10.1002/phy2.230
  15. Jorsal A, Tarnow L, Frystyk J, et al. Serum adiponectin predicts all-cause mortality and end stage renal disease in patients with type I diabetes and diabetic nephropathy. Kidney Int 2008;74:649-654. https://doi.org/10.1038/ki.2008.201
  16. Menon V, Li L, Wang X, et al. Adiponectin and mortality in patients with chronic kidney disease. J Am Soc Nephrol 2006;17:2599-2606. https://doi.org/10.1681/ASN.2006040331
  17. Looker HC, Krakoff J, Funahashi T, et al. Adiponectin concentrations are influenced by renal function and diabetes duration in Pima Indians with type 2 diabetes. J Clin Endocrinol Metab 2004;89:4010-4017. https://doi.org/10.1210/jc.2003-031916
  18. Martinez Cantarin MP, Keith SW, Waldman SA, Falkner B. Adiponectin receptor and adiponectin signaling in human tissue among patients with end-stage renal disease. Nephrol Dial Transplant 2014;29:2268-2277. https://doi.org/10.1093/ndt/gfu249
  19. Guebre-Egziabher F, Bernhard J, Funahashi T, Hadj-Aissa A, Fouque D. Adiponectin in chronic kidney disease is related more to metabolic disturbances than to decline in renal function. Nephrol Dial Transplant 2005;20:129-134. https://doi.org/10.1093/ndt/gfh568
  20. Martinez Cantarin MP, Waldman SA, Doria C, et al. The adipose tissue production of adiponectin is increased in end-stage renal disease. Kidney Int 2013;83:487-494. https://doi.org/10.1038/ki.2012.421
  21. Herder C, Bongaerts BW, Rathmann W, et al. Differential association between biomarkers of subclinical inflammation and painful polyneuropathy: results from the KORA F4 study. Diabetes Care 2015;38:91-96. https://doi.org/10.2337/dc14-1403
  22. Ussar S, Bezy O, Bluher M, Kahn CR. Glypican-4 enhances insulin signaling via interaction with the insulin receptor and serves as a novel adipokine. Diabetes 2012;61:2289-2298. https://doi.org/10.2337/db11-1395
  23. Yoo HJ, Hwang SY, Cho GJ, et al. Association of glypican- 4 with body fat distribution, insulin resistance, and nonalcoholic fatty liver disease. J Clin Endocrinol Metab 2013;98:2897-2901. https://doi.org/10.1210/jc.2012-4297
  24. Watanabe K, Yamada H, Yamaguchi Y. K-glypican: a novel GPI-anchored heparin sulfate proteoglycan that is highly expressed in developing brain and kidney. J Cell Biol 1995;130:1207-1218. https://doi.org/10.1083/jcb.130.5.1207
  25. Strate I, Tessadori F, Bakkers J. Glypican4 promotes cardiac specification and differentiation by attenuating canonical Wnt and Bmp signaling. Development 2015;142:1767-1776. https://doi.org/10.1242/dev.113894
  26. Chang GY, Park AS, Susztak K. Tracing the footsteps of glomerular insulin signaling in diabetic kidney disease. Kidney Int 2011;79:802-804. https://doi.org/10.1038/ki.2010.559
  27. Hirakawa Y, Arima H, Zoungas S, et al. Impact of visit- to-visit glycemic variability on the risks of macrovascular and microvascular events and all-cause mortality in type 2 diabetes: the ADVANCE trial. Diabetes Care 2014;37:2359-2365. https://doi.org/10.2337/dc14-0199
  28. Muggeo M, Zoppini G, Bonora E, et al. Fasting plasma glucose variability predicts 10-year survival of type 2 diabetic patients: the Verona Diabetes Study. Diabetes Care 2000;23:45-50. https://doi.org/10.2337/diacare.23.1.45
  29. Ceriello A, Esposito K, Piconi L, et al. Oscillating glucose is more deleterious to endothelial function and oxidative stress than mean glucose in normal and type 2 diabetic patients. Diabetes 2008;57:1349-1354. https://doi.org/10.2337/db08-0063
  30. Wu J, Bostrom P, Sparks LM, et al. Beige adipocytes are a distinct type of thermogenic fat cell in mouse and human. Cell 2012;150:366-376. https://doi.org/10.1016/j.cell.2012.05.016
  31. Roca-Rivada A, Castelao C, Senin LL, et al. FNDC5/irisin is not only a myokine but also an adipokine. PLoS One 2013;8:e60563. https://doi.org/10.1371/journal.pone.0060563
  32. Liu JJ, Wong MD, Toy WC, et al. Lower circulating irisin is associated with type 2 diabetes mellitus. J Diabetes Complications 2013;27:365-369. https://doi.org/10.1016/j.jdiacomp.2013.03.002
  33. Liu JJ, Liu S, Wong MD, et al. Relationship between circulating irisin, renal function and body composition in type 2 diabetes. J Diabetes Complications 2014;28:208-213. https://doi.org/10.1016/j.jdiacomp.2013.09.011
  34. Li DJ, Huang F, Lu WJ, Jiang GJ, Deng YP, Shen FM. Metformin promotes irisin release from murine skeletal muscle independently of AMP-activated protein kinase activation. Acta Physiol (Oxf ) 2015;213:711-721. https://doi.org/10.1111/apha.12421
  35. Moschen AR, Kaser A, Enrich B, et al. Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J Immunol 2007;178:1748-1758. https://doi.org/10.4049/jimmunol.178.3.1748
  36. Kang YS, Cha DR. The role of visfatin in diabetic nephropathy. Chonnam Med J 2011;47:139-143. https://doi.org/10.4068/cmj.2011.47.3.139
  37. Vikram NK, Misra A, Pandey RM, et al. Anthropometry and body composition in northern Asian Indian patients with type 2 diabetes: receiver operating characteristics (ROC) curve analysis of body mass index with percentage body fat as standard. Diabetes Nutr Metab 2003;16:32-40.
  38. Kollerits B, Fliser D, Heid IM, Ritz E, Kronenberg F; MMKD Study Group. Gender-specific association of adiponectin as a predictor of progression of chronic kidney disease: the Mild to Moderate Kidney Disease Study. Kidney Int 2007;71:1279-1286. https://doi.org/10.1038/sj.ki.5002191

Cited by

  1. Adipocytokines and new onset diabetes mellitus after transplantation vol.16, pp.4, 2018, https://doi.org/10.1016/j.jab.2018.05.005
  2. Adiponectin for the treatment of diabetic nephropathy vol.34, pp.3, 2019, https://doi.org/10.3904/kjim.2019.109
  3. Relationship between diabetic polyneuropathy, serum visfatin, and oxidative stress biomarkers vol.11, pp.7, 2018, https://doi.org/10.4239/wjd.v11.i7.309
  4. Fasting Glucose of 6.1 mmol/L as a Possible Optimal Target for Type 2 Diabetic Patients with Insulin Glargine: A Randomized Clinical Trial vol.2021, pp.None, 2018, https://doi.org/10.1155/2021/5524313
  5. Glypican-4 in pregnancy and its relation to glucose metabolism, insulin resistance and gestational diabetes mellitus status vol.11, pp.1, 2018, https://doi.org/10.1038/s41598-021-03454-x
  6. Fasting Glucose Variability as a Risk Indicator for End-Stage Kidney Disease in Patients with Diabetes: A Nationwide Population-Based Study vol.10, pp.24, 2018, https://doi.org/10.3390/jcm10245948